| Literature DB >> 35116762 |
Peng Guo1,2, Shengtao Liao3, Jianwei Li2, Shuguo Zheng2.
Abstract
Primary hepatocellular carcinoma (HCC) is a common malignant tumor in China and is often accompanied by portal hypertension (PHT). Whether simultaneous operation can be used in patients with liver cirrhosis and PHT accompanied by HCC is controversial. The aim of the present study was to investigate the safety and feasibility of simultaneous laparoscopic hepatectomy, splenectomy and pericardial devascularization in the treatment of HCC with PHT. A total of 16 patients were treated with laparoscopic surgery for PHT and HCC from April 2011. The operation time, volume of intraoperative blood loss, red blood cell transfusion, plasma transfusion, time for diet intake, drainage time, duration of hospital stay and occurrence of complications were observed. The follow-up time was 3 years, and long-term outcomes included overall survival rates and recurrence-free survival rates. The operation time and volume of blood loss were 336±18 min and 337±351 mL, respectively. Of the patients, 2 received intraoperative homologous blood transfusion and 9 received plasma transfusion. The time for diet intake, drainage time and duration of hospital stay were 3.5±0.5, 7.3±1.0 and 13.6±3.6 days, respectively. The postoperative complications included 1 patient with anastomosis-site bleeding, 2 patients with abdominal effusion and 3 patients with portal vein thrombosis, which were treated conservatively. The overall survival rates at 1 and 3 years were 100% (16/16) and 87.5% (14/16), respectively. The recurrence-free survival rates at 1 and 3 years were 87.5% (14/16) and 62.5% (10/16), respectively. In conclusion, simultaneous laparoscopic hepatectomy, splenectomy and pericardial devascularization is an effective treatment for PHT and primary HCC, and provides a potential new therapy for patients. 2019 Translational Cancer Research. All rights reserved.Entities:
Keywords: Laparoscopic surgery; hepatectomy; hepatocellular carcinoma (HCC); portal hypertension (PHT); splenectomy
Year: 2019 PMID: 35116762 PMCID: PMC8797662 DOI: 10.21037/tcr.2019.01.23
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Clinical characteristics of the patients
| Indicators | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | Patient 13 | Patient 14 | Patient 15 | Patient 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Male | Female | Male | Male | Male | Female | Female | Male | Male | Female | Male | Female | Female | Male | Female | Male |
| Age (years) | 45 | 63 | 54 | 31 | 57 | 49 | 55 | 56 | 67 | 62 | 58 | 29 | 70 | 58 | 62 | 45 |
| Child-Pugh Class | A | A | B | A | A | A | B | A | A | B | A | A | A | B | A | A |
| HCC | ||||||||||||||||
| Liver segment | IVa | VI | VIII | V | VI | VIII | V | VI | IVb | VI | VII | V | VIII | IVa | V | VI |
| Tumor diameter (cm) | 3.5 | 3.8 | 4.8 | 2.5 | 3 | 4.5 | 5 | 2 | 5 | 3.5 | 1 | 3 | 2 | 1.5 | 2 | 1.5 |
| Upper gastrointestinal hemorrhage | ||||||||||||||||
| Hematemesis (times) | 2 | 1 | 0 | 0 | 0 | 3 | 0 | 2 | 4 | 1 | 1 | 0 | 0 | 1 | 2 | 1 |
| Melena (times) | 0 | 2 | 3 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 3 | 0 | 2 | 0 | 1 |
| Operation date | 2011/5/3 | 2011/4/21 | 2011/11/16 | 2012/9/7 | 2013/5/10 | 2014/3/14 | 2013/8/6 | 2013/10/24 | 2013/4/9 | 2013/3/28 | 2013/8/1 | 2015/5/11 | 2014/12/17 | 2014/12/9 | 2014/8/29 | 2014/6/3 |
| ALT (IU/L) | 26 | 27 | 16 | 37 | 32 | 41 | 64 | 44 | 28 | 48 | 29 | 15 | 23 | 44 | 72 | 35 |
| AST (IU/L) | 31 | 42 | 35 | 51 | 34 | 45 | 47 | 37 | 47 | 54 | 38 | 34 | 31 | 52 | 84 | 55 |
| Albumin (g/L) | 44 | 37.4 | 31.9 | 35.6 | 36.3 | 35.1 | 39.7 | 32.5 | 42 | 31.8 | 35.4 | 37.6 | 46.3 | 37 | 33.9 | 30.6 |
| Hemoglobin (g/L) | 114 | 94 | 81 | 103 | 112 | 108 | 98 | 109 | 95 | 112 | 89 | 108 | 102 | 93 | 89 | 105 |
| White blood cells (109 cells/L) | 2.97 | 1.27 | 2.17 | 1.71 | 2.16 | 1.93 | 1.85 | 2.3 | 1.94 | 2.11 | 1.76 | 1.57 | 1.87 | 2.03 | 1.92 | 2.4 |
| Blood platelets (109 cells/L) | 29 | 23 | 16 | 21 | 35 | 19 | 24 | 28 | 21 | 26 | 22 | 19 | 20 | 27 | 23 | 26 |
| AFP (ng/mL) | 19 | 379 | 481 | >1,210 | 498 | >1,210 | 9 | 59 | 993 | 36.5 | 485 | >1,210 | 4.5 | 20 | 192 | 3 |
| ICGR15 (%) | 9.8 | 21 | 40 | 52 | 46 | 63 | 8.3 | 18 | 53 | 36 | 42 | 50 | 12 | 15 | 28 | 16 |
| HBV-DNA (copy/mL) | 130 | 500 | 422 | 2,500 | <500 | 3,600 | 260 | 313 | 185 | 406 | 341 | 168 | 220 | 430 | 279 | 194 |
HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha fetal protein; ICGR15, indocyanine green retention rate at 15 min.
Figure 1Surgical positions in splenectomy and hepatectomy. For splenectomy, the left side of the body was positioned higher than the right side by 30°, and the head was placed higher than the feet by 15°. For hepatectomy, the right side of the body was placed higher than the left side by 30°, while the head was positioned higher than the feet by 15° (by adjusting the surgical bed).
Figure 2Locations of trocar holes. (A) 10 mm, for laparoscope; (B) 12 mm, for main operations in hepatectomy; (C) 12 mm, for main operations in splenectomy and pericardial devascularization. The wound was expanded to 3 cm when the spleen and liver tumor were removed from the abdominal cavity; (D) 5 mm, for auxiliary operations in hepatectomy; (E) 5 mm, for assistant’s operations in splenectomy; (F) 5 mm, for assistant’s operations; (G) 5 mm, for assistant’s operations.
Clinical characteristics of all the patients during and subsequent to operation
| Indicators | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | Patient 13 | Patient 14 | Patient 15 | Patient 16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| During operation | ||||||||||||||||
| Duration (min) | 336 | 354 | 306 | 356 | 342 | 339 | 360 | 325 | 309 | 312 | 328 | 341 | 352 | 324 | 334 | 362 |
| Blood loss (mL) | 150 | 1,500 | 200 | 180 | 230 | 350 | 400 | 200 | 200 | 300 | 150 | 300 | 150 | 200 | 800 | 80 |
| RBC transfusion (mL) | 0 | 1,200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 600 | 0 |
| Plasma transfusion (mL) | 0 | 740 | 0 | 500 | 450 | 500 | 500 | 0 | 0 | 500 | 0 | 500 | 0 | 400 | 500 | 0 |
| Spleen size (cm3) | 1,936 | 1,462.50 | 1,840 | 2,079 | 1,400 | 1,540 | 2,024 | 1,680 | 1,748 | 1,955 | 1,760 | 2,280 | 1,881 | 2,376 | 2,475 | 1,260 |
| Tumor diameter (cm) | 2 | 2.5 | 4.8 | 2 | 2.5 | 4.8 | 3 | 2.9 | 3.6 | 2.5 | 3.6 | 4 | 3.8 | 3.2 | 4.4 | 3.2 |
| Resection range (cm)a | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Postoperation | ||||||||||||||||
| Oral intake (days) | 3 | 4 | 3 | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 3 | 3 | 4 | 3 |
| Drainage time (days) | 6 | 9 | 7 | 6 | 7 | 8 | 8 | 7 | 7 | 9 | 6 | 6 | 7 | 8 | 7 | 8 |
| Hospital stay (days) | 9 | 24 | 11 | 10 | 12 | 13 | 14 | 12 | 14 | 19 | 12 | 13 | 14 | 14 | 11 | 15 |
a, distance from tumor margin. RBC, red blood cell.